Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: A pharmacological puzzle

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 558-561

  Railton, Craig J ^a   Kapur, Bhushan ^a,b   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Drug monitoring; Hemodialysis; Peritoneal dialysis; Risperidone

Indexed keywords

CALCITRIOL; CLONAZEPAM; CLONIDINE; FLUOXETINE; OMEPRAZOLE; RISPERIDONE; WARFARIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MINIMAL CHANGE GLOMERULONEPHRITIS; OBSESSIVE COMPULSIVE DISORDER; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SYMPTOMATOLOGY; TIC;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; ISOXAZOLES; PYRIMIDINES; RENAL DIALYSIS; RISPERIDONE; TICS;

EID: 26444539079     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000168720.19867.43     Document Type: Article

References (13)

1. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26:201-214.
2. Llerena A, Dorado P, Berecz R, et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetien plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004;59:869-873.
3. Cohen LJ. Risperidone. Pharmacotherapy. 1994;14:253-265.
4. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151.
5. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999;60:469-476.
6. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol. 1996;16:177-187.
7. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22:419-423.
8. Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients. Pharmacopsychiatry. 2002;35:50-56,
9. Berecz R, Llernena A, de la Rubia A, et al. Relationship between risperidone and 9-hydroxyrisperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry. 2002;35:231-234.
10. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57:671-675.
11. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B. 1997;698:209-216.
12. Titier K, Deridet E, Cardone E, et al. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose. J Chromatogr B. 2002;772:373-378.
13. Balant-Gorgia AE, Gex-Fabry M, Genet C, et al. Therapeutic drug monitoring of riperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit. 1999;21:105-115.